Mineralys Therapeutics, Inc. · NASDAQ:MLYS

Mineralys Therapeutics — Technical Presentation (June 2025)

19 slides from Mineralys Therapeutics's technical presentation, Jun 17, 2025

1. Slide 1: Targeting Aldosterone in the Treatment of Cardiorenal Diseases

   Targeting Aldosterone in the Treatment of Cardiorenal Diseases Explore-CKD Phase 2 Trial Topline Data June 17, 2025 © 2025 Mineralys Therapeutics, Inc. All Rights Reserved. © 2025 Mineralys Therapeutics, Inc.

2. Slide 2: Forward-Looking Statements and Market Data

   Forward-Looking Statements and Market Data Mineralys Therapeutics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include,

3. Slide 3: Agenda

   Introduction 01 Jon Congleton, CEO of Mineralys Therapeutics Explore-CKD Data 02 Dr. David Rodman, M.D., CMO of Mineralys Therapeutics Agenda 03 Hypertension in CKD and Emerging Treatments Dr. Matthew Weir, Div. Head of Nephrology Univ. of Maryland School of Medicine Conclusion 04 Jon Congleton 05 Q

4. Slide 4: Positive Topline Results from Explore-CKD

   Positive Topline Results from Explore-CKD • Explore-CKD is the FOURTH positive clinical trial of lorundrostat completed in uHTN or rHTN • 25mg lorundrostat demonstrated a meaningful BP benefit assessed by automated office BP at end of treatment, week 4 • Reduction in UACR comparable to recent trials

5. Slide 5: Lorundrostat Development Program with Positive Pivotal Data and Market Expansion Proof-of-Concept Trials

   Lorundrostat Development Program with Positive Pivotal Data and Market Expansion Proof-of-Concept Trials TRIAL SAFETY PROOF OF CONCEPT PIVOTAL KEY MILESTONES Hypertension -15.4 mmHg absolute change in SBP at uHTN & rHTN Standardized background AHT COMPLETED Week 12 Hypertension -19.0 mmHg absolute c

6. Slide 6: CKD Proof-of-Concept and Profiling Trial

   CKD Proof-of-Concept and Profiling Trial Proof-of-Concept in hypertensive nephropathy aimed to demonstrate benefit on blood pressure and kidney function 2 WEEK RUN-IN 4 WEEKS 4 WEEKS 4 WEEKS Background regimen including SGLT2 inhibitor and ACE inhibitor or ARB LORUNDROSTAT 25MG WASHOUT PLACEBO QD In

7. Slide 7: Baseline Demographics

   Baseline Demographics 65 69% 66% 17% Male White Black or African Years (mean age) American 76% 33 kg/m 2 54.6 ml/min/1.73m 2 Diabetes Mean BMI Mean eGFR (Creatinine) 516 mg/g 149 mmHg Geometric Mean Spot Mean Systolic AOBP Urine UACR © 2025 Mineralys Therapeutics, Inc. 7

8. Slide 8: Explore-CKD Efficacy

   Explore-CKD Efficacy © 2025 Mineralys Therapeutics, Inc. All Rights Reserved. © 2025 Mineralys Therapeutics, Inc.

9. Slide 9: Clinically Meaningful Systolic BP Reduction at 4 Weeks with 25mg QD

   Clinically Meaningful PLACEBO LORUNDROSTAT 50mg Systolic BP Reduction at 0 4 Weeks with 25mg QD -1 -1.8 SBP Change from baseline (mmHg) -2 PLACEBO ABSOLUTE ABSOLUTE VALUE VALUE • SysBP measured in office (AOBP) -3 • Absolute reduction in systolic BP -4 of 9.3 mmHg -5 • Placebo-adjusted change in -6

10. Slide 10: Reduction in Proteinuria Demonstrated with UACR

    Reduction in PLACEBO LORUNDROSTAT Proteinuria 0 Demonstrated with UACR % Change from baseline (wk 4) -5 -6.6 Lorundrostat is a Surrogate for Renal -10 Protection -15 • 31% reduction in spot UACR (p < 0.0001) -20 -25 -30 -30.5 -35 © 2025 Mineralys Therapeutics, Inc. 10

11. Slide 11: Explore-CKD Safety

    Explore-CKD Safety © 2025 Mineralys Therapeutics, Inc. All Rights Reserved. © 2025 Mineralys Therapeutics, Inc.

12. Slide 12: Modest change in potassium in renally impaired population

    Confirmed Hyperkalemia Modest change in potassium in renally SERUM PLACEBO 25 mg QD* POTASSIUM impaired population (mmol/L) (N=59) (N=58) ≤5.5 58 (98.3) 51 (87.9) • Mean change in potassium of 0.5 mmol/L in lorundrostat treatment periods >5.5 1 (1.7) 7 (12.1) • One subject with potassium >6.5 mmol/L

13. Slide 13: Modest change in mean eGFR (Cys-C)

    PLACEBO LORUNDROSTAT Modest change in 0 mean eGFR (Cys-C) eGFR (Cys-C) % change from baseline -1 consistent with that -2.2 observed in the -2 Launch-HTN trial -3 -4 • One subject with low eGFR discontinued (1.7%) -5 -6 -6.8 -7 -8 © 2025 Mineralys Therapeutics, Inc. 13

14. Slide 14: Low incidence of Adverse Event of Special Interest and SAEs

    Adverse Events of Special Interest Low incidence of PLACEBO LORUNDROSTAT 25 mg QD Adverse Event of (N=57) (N=58) Special Interest % N Events % N Events and SAEs Hyperkalemia 0 0 0 8.6 5* 5 SAEs: Hyponatremia 1.8 1 1 1.7 1 1 • 2 (3%) subjects during lorundrostat treatment period Severely elevated BP

15. Slide 15: Conclusion

    • Meaningful absolute reduction in systolic BP of 9.3 mmHg and placebo adjusted of 7.5 mmHg at week 4 with 25mg dosed once daily • Meaningful reduction in UACR of 31% a key surrogate of kidney protection • Manageable safety with only two subjects discontinuing lorundrostat treatment • Well-tolerated

16. Slide 16: Matthew R. Weir, M.D.

    • Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital and Professor of Matthew R. Weir, M.D. Medicine at the University of Maryland School of Medicine. Professor of Nephrology • Dr. Weir’s primar

17. Slide 17: Lorundrostat Data Demonstrate a Consistent, Clinically Meaningful Profile

    Lorundrostat Data Demonstrate a Consistent, Clinically Meaningful Profile with the Potential to Benefit a Spectrum of Hypertension Patients Lorundrostat Clinical Program Compromised Kidney Intent of Trial Real world Specialist Function Size of the trial 1,083 285 60 4 wk treatment, 12 wks PBO 12 wks

18. Slide 18: Q&A

    Q&A Mineralys Therapeutics, Inc. ©2025. All Rights Reserved. 18

19. Slide 19: Mineralys Therapeutics, Inc. ©2025. All Rights Reserved.

    Mineralys Therapeutics, Inc. ©2025. All Rights Reserved. 19

Mineralys Therapeutics — Technical Presentation (June 2025) on 6ix